Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment
← catalyst calendarSponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Design
Na · None · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study redesigned and registered under NCT07245992 (Protocol n° PH-F8IL10INTRA-03/24)
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-31 | estimated | When the study began enrolling |
| Primary completion | 2025-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rheumatoid Arthritis
Intervention
- Drug: F8IL10 — also filed as Dekavil
Primary outcomes
what the primary-completion date above is the date OFMTD
measured From the enrollment of each patient until the completion of the treatment (for a maximum of 9 weeks)
RD
measured From the enrollment of each patient until the completion of the treatment (for a maximum of 9 weeks)
Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed